DANIEL BRADBURY
CIK 1236397 · CHAIRMAN · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.19M
Companies
11
Total Filings
275
Lifetime Open-Market Net
-$176.51M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VANI | Director | — | $1.31 | — | $0 | 7 | 2026-06-25 |
| CSTL | Director | 35,631 | $23.89 | $851.2K | -$160.98M | 91 | 2026-06-01 |
| EQ | CHAIRMAN | 2,969,596 | $2.32 | $6.89M | $0 | 11 | 2026-05-29 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 39,471 | $19.00 | $749.9K | $500.0K | 9 | 2023-05-25 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 25,000 | $0.01 | $128 | $0 | 1 | 2021-02-26 |
| GERN | Director | 51,323 | $1.45 | $74.4K | $0 | 12 | 2019-04-01 |
| CORT | Director | 130,575 | $94.19 | $12.30M | -$480.2K | 16 | 2019-02-12 |
| ILMN | Director | 15,924 | $192.98 | $3.07M | -$14.97M | 79 | 2017-05-26 |
| BMR | Director | 4,139 | $1.22 | $5.0K | $0 | 1 | 2013-01-03 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | President & Chief Executive Of | 127,235 | — | — | -$574.8K | 30 | 2012-07-26 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | 35,714 | — | — | $0 | 3 | 2008-02-15 |
Recent Filings · Page 2 of 28
275 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-08 | CSTL | Sell (S) | −7,867 | -$229.2K | EDGAR |
| 2025-01-06 | EQ | Grant (A) | — | $0 | EDGAR |
| 2025-01-03 | VANI | Grant (A) | — | $0 | EDGAR |
| 2024-12-05 | CSTL | Sell (S) | −7,867 | -$243.7K | EDGAR |
| 2024-12-03 | CSTL | Notice (144) | −15,734 | -$484.3K | EDGAR |
| 2024-11-05 | CSTL | Sell (S) | −7,867 | -$273.3K | EDGAR |
| 2024-10-09 | CSTL | Sell (S) | −7,867 | -$231.6K | EDGAR |
| 2024-10-07 | CSTL | Notice (144) | −15,734 | -$464.5K | EDGAR |
| 2024-09-09 | CSTL | Sell (S) | −7,867 | -$228.3K | EDGAR |
| 2024-08-14 | CSTL | Sell (S) | −7,883 | -$210.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.